



सत्यमेव जयते

National Institute of Biologicals, Noida
(NCC- HvPI)
Ministry of Health and Family Welfare,
Govt. of India

75
Azadi Ka
Amrit Mahotsav

HAEMOVIGILANCE NEWSLETTER

Haemovigilance Programme of India



*Release of First Guidance Document for Reporting Blood Donor Adverse Reactions by
Dr. Bharti Pravin Pawar, Hon'ble Minister of State, Ministry of Health & Family Welfare,
Govt. of India*

Haemovigilance Newsletter Vol. No. 10 Issue 20, July-December, 2022

03

Haemovigilance
Programme of
India-Milestones

04

Online Webinar/
Institutional representation
under HvPI

05

Article on
Transfusion
Medicine Clinic

08

First Donor
Guidance
Document

“The aim of the newsletter is to disseminate information on Haemovigilance Programme of India so as to create awareness amongst healthcare professionals & other stakeholders on safe Blood Transfusion & Blood Donation Practices”

Editor:

Dr. Akanksha Bisht,
Scientist Grade-II & Head,
Haemovigilance Programme of
India (HvPI), NIB, NOIDA

Editorial Board:

1. **Prof.(Dr.) Ravneet Kaur,**
Head, Department of
Transfusion Medicine,
Government Medical
College and Hospital,
Chandigarh
2. **Dr. Paras Jain,**
Junior Scientist, NIB,
NOIDA
3. **Mr. Reetesh Kumar,**
Laboratory Technician, NIB,
NOIDA

Expert Reviewers:

1. **Dr. Neelam Marwaha**
Former Professor & Head, Department of
Transfusion Medicine, Post Graduate
Institute of Medical Education & Research,
Chandigarh
2. **Prof. (Dr.) Jayashree Sharma**
Head, Department of Transfusion Medicine,
Seth G.S. Medical College & KEM Hospital,
Mumbai, Maharashtra
3. **Prof. (Dr.) U. B. Mishra**
Head, Dept. of Hospital Administration,
KGMU, Lucknow
4. **Dr. U.C. Dutta**
Director Blood Bank, Rahman Hospitals Pvt.
Ltd., Guwahati, Assam
5. **Prof. (Dr.) D. R. Arya**
Head, Dept. of Transfusion Medicine, S.P.
Medical College & A.G. Hospital, Bikaner
6. **Dr. C. Shivaram**
Consultant & Head, Transfusion Medicine,
Manipal Hospitals, Bangalore
7. **Prof. (Dr.) Vijay Sawhney**
Head, Dept. of Transfusion Medicine,
Government Medical College Jammu
8. **Dr. G. Selvaraj**
Former Director, Drugs Controller, Tamil
Nadu
9. **Dr. Irfana Nikhat**
Consultant & Head, Star Hospitals Blood
Centre, Hyderabad
10. **Prof. (Dr.) Shamee Shastri**
Head, Department of Immunohematology
and Blood Transfusion, KMC, Manipal
University, Manipal

Table of Contents

Haemovigilance Programme of India-Milestones.....	3
Online webinar/ Institutional representation under Haemovigilance Programme.....	4
Article on Transfusion Medicine Clinic.....	5
Published Article	7
Release of First Guidance Document for Reporting Blood Donor Adverse Reactions.....	8
Meetings.....	9
New Members Enrolled under Haemovigilance Programme of India.....	10
How to Enroll your Centre under HvPI.....	15

Haemovigilance Programme of India - Milestones

Haemovigilance Programme of India was launched on 10th December, 2012 at the National level in 90 medical institutions across the country by National Institute of Biologicals (NIB), NOIDA, Ministry of Health & Family Welfare, Government of India as the National Coordinating Centre (NCC). The objective of this programme is to track Adverse Reactions associated with Blood Transfusion and Blood Donation.

Haemovigilance is defined as 'a set of surveillance procedures covering the whole transfusion chain from the collection of blood and its components to the follow-up of its recipients i.e. from the vein of the donor to the vein of the recipient. It is intended to collect and assess information on unexpected or undesirable effects resulting from the therapeutic use of labile blood products and to prevent their occurrence and recurrence'. Haemovigilance is a tool to improve the quality of the blood transfusion chain, primarily focusing on safety.

1. The recipient's arm i.e. reporting of Adverse Reactions with respect to Blood Transfusion in the patient is being covered under **Haemovigilance Programme of India (HvPI)** with the launch of the programme on 10th December, 2012 in the country.
2. The donor's arm i.e. Reporting of Adverse Reactions associated with Blood Donations is being covered under **National Blood Donor Vigilance Programme (NBDVP)** which was launched on 14th June, 2015 on World Blood Donor Day at Science City Kolkata under the ambit of HvPI.
3. Reporting of Adverse Transfusion Reactions is done online via Haemo-Vigil software & reporting of Adverse Blood Donor Reactions is done via Donor-Vigil software available on NIB website www.nib.gov.in

Implementation and coordination of activities of Haemovigilance Programme of India became one of the Mandate's of NIB as per its bye-laws 3.4.1 of the Institute as approved in the Governing Body meeting of NIB held under chairpersonship of Secretary (Health & F.W.)/ Chairman, Governing Body of NIB on 12th Dec, 2014

DCG (I) issued an office memorandum dated 4th December, 2015 w.r.t. enrolment of all licensed blood centres under HvPI. These licensed blood centres are required to obtain their user ID and password from NIB to uplink their adverse transfusion data to Haemo-Vigil software under HvPI.

National Accreditation Board for Hospitals and Healthcare Providers (NABH) in its third edition of accreditation standards on Blood Centres and transfusion services issued in year 2016 has included enrolment by Blood Centres under National Haemovigilance Program of India and monitor adverse donor reactions and adverse transfusion reactions as per the direction issued.

NCC-HvPI, NIB issues certificate of participation to the centres who are actively reporting under Haemovigilance Programme of India.

Online Webinar under Haemovigilance Programme of India (HvPI)

- ❖ A webinar for 50 blood centres w.r.t. Severity Grading Tool (SGT) study under National Blood Donor Vigilance Programme (NBDVP) was organized by Haemovigilance Division of NIB on 06th April, 2022 to discuss the SGT study cases with explanation. Apart from participating centres, experts from transfusion medicine department also attended the said webinar.



Institutional representation under Haemovigilance Programme of India (HvPI)

- ❖ Talk on “Journey of Haemovigilance Programme of India (HvPI)” delivered by Head HvPI via online mode on 20th May, 2022 during 2nd North East Workshop on Haemovigilance, Blood Donor Vigilance & on Voluntary Blood Donation organised by Barak Valley Voluntary Blood Donor’s Forum central committee & supported by Federation of Blood Donor Organizations of India (FBDIO) held on 20th -21st May, 2022 at Silchar, Assam.



- ❖ Head-HvPI delivered an online presentation on the topic “NIB- What is Haemovigilance & What Role can FIBDO play for blood safety” on 28th May, 2022 in the Federation of Indian Blood Donors Organisations (FIBDO) West Bengal State Conference- 2022 organized by FIBDO, West Bengal held on 28th-29th May 2022 at Barasat Rabindra Bhawan in North 24 Parganas.



Topic: TRANSFUSION MEDICINE CLINIC

Author Name: Dr. Prasun Bhattacharya,

Designation: Professor and Head

Organization: Dept. of Immunohematology and Blood Transfusion, Medical College Kolkata, 700073



Transfusion of blood and its components are an essential part of any health care facility. In the last two decades our country has progressed immensely in terms of blood component preparation and its applications. Incorporation of new technologies, creating transfusion medicine departments and introducing the capacity building approach adhered to the objectives of National Blood Policy have immensely improved the scenario of blood transfusion services. It has reduced both the short- and long-term complications of blood transfusion. To monitor and generate evidence-based recommendations to minimize the adverse events of blood transfusion the National Haemovigilance program was established on December 10, 2012.¹ The nomenclature of blood banks is now replaced to blood centre by the Central Drugs Standard Control organization (CDSCO), the national regulatory authority, for drug under the Ministry of Health and Family Welfare. Presently there are more than 22 blood components/facilities which are licensed in India and in future the blood centres have the potential to generate many newer generations of blood components.²

However, the knowledge, attitude and practice related to the use of blood components across our medical fraternity should not remain static as this specialized medical discipline is not included in the undergraduate curriculum, nor it is still linked to the direct patient care. The centres having transfusion medicine departments should become more pro-active and forward their expertise for better patient care. Patient hemovigilance reporting is incomplete in most of the time unless it is assessed by a transfusion medicine physician. There is a huge scope of improvement in quality of patient care as blood component transfusion is one of the commonest in-patient interventions and allogenic transfusion is no less than a tissue transplant.

The department of Immunohaematology and Blood transfusion (IHBT) was established on July 26, 2010, at Calcutta Medical College Hospital blood bank (now blood centre), in West Bengal with introduction of post-graduate MD in IHBT in 2011. Till now it is the only academic centre in the densely populated state which is consistently providing the services and consultation to the different medical specialties related to the rational application of blood components and their potential hazards. Moreover, our approach to the rational application of convalescent plasma in severe Covid19 patients with ARDS has been recognized by many premier scientific body/institutions across the world.^{3,4,5}

Considering our credentials and the faculties' background of direct patient care we were approached by the State Blood cell, National Health Mission (NHM) and State blood transfusion council (SBTC) to provide a day care and indoor patient services on June 9, 2021. The services were initially targeted to the haemoglobinopathy, congenital bleeding/coagulation disorders and better patient care to those who require specialised components like leuko-reduction and extended phenotype matched red cells.

Cont...

To a practical approach to the patient care delivery the Dept. IHBT, Medical College Kolkata started its first OPD services as Transfusion Medicine Clinic on 06.04.2022 and on every Wednesday 9.00 am - 2.00 pm. Our scope of services presently involves:

1. Post-transfusion follow-up clinic to determine both long- and short-term effects of blood transfusion especially in transfusion dependent patients and cancer chemotherapy
2. Pre-operative anaemia and patient blood management
3. Antenatal mothers screening
4. Patients who have poor tolerance to blood component therapy (viz. alloimmunization, recurrent transfusion reactions, platelet refractoriness etc.)
5. Blood donor related services (deferred blood donors, donor adverse events and post donation counselling)
6. Specialised blood component support in critical patients and regenerative medicine clinic

In the long term we expect that the importance of the transfusion services shall be more significant in the tertiary health care facility having solid organ and bone marrow transplant facilities.

Similar initiatives are essential across the country in every teaching institution for the betterment of the transfusion services and exploring the newer horizons of quality and patient safety.

References

1. Bisht A, Singh S, Marwaha N. Haemovigilance Program – India. Asian J transfu Sci; 7(1): 73 -74
2. cdsco.gov.in (accessed on 04.07.2022)
3. Biswas D, Maiti C, Talukder B, Azharuddin M, Saha S, Pandey S et al. A prospective study on COVID-19 convalescent plasma donor (CCP) recruitment strategies in a resource constrained blood centre. ISBT Sci Ser. 2021 Jun 1;10.1111/voxs.12639. doi: 10.1111/voxs.12639. Epub ahead of print. PMID: 34226835; PMCID: PMC8242402.
4. Bandopadhyay P, D’Rozario R, Lahiri A, Sarif J, Ray Y, Paul SR, et al. Nature and Dimensions of Systemic Hyperinflammation and its Attenuation by Convalescent Plasma in Severe COVID-19. J Infect Dis. 2021 Aug 16;224(4):565-574. doi: 10.1093/infdis/jiab010. PMID: 34398242; PMCID: PMC7928875.
5. Ray Y, Paul SR, Bandopadhyay P, D’Rozario R, Sarif J, Raychaudhuri D, Bhowmik D et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nat Commun. 2022 Jan 19;13(1):383. doi: 10.1038/s41467-022-28064-7. PMID: 35046397; PMCID: PMC8770561.

International Conference/Seminar

- ❖ Head- HvPI being the Secretary of International Haemovigilance Network (IHN) attended the GAPP (facilitating the Authorisation of Preparation Process for blood, tissues and cells), final Dissemination Conference online with the host location Thessaloniki, Greece on 20th & 21st January 2022.
- ❖ Head- HvPI being the Secretary of IHN board attended 2022 virtual mini-seminar of the International Hemovigilance Network on plasma vigilance organized by IHN held on 29th March 2022.

Published Article

An article on “First Decade of implementation of Haemovigilance Programme in India” has been published in Transfusion Today, Number 131, April 2022 Issue of International Society of Blood Transfusion (ISBT).





National Skill Development & Hands-on Training Programme on Quality Control of Biologicals for M.Sc. Biotechnology Students from 06th June to 17th June, 2022 at NIB, NOIDA.

The Students from Sant Gahira Guru Vishwavidyalaya, Sarguja Ambikapur (Chhattisgarh) & Bodoland University, Kokrajhar (Assam) participated in the said training programme. One session during this training programme was kept for Haemovigilance Programme of India on 16th June, 2022. During this session students were apprised about Haemovigilance Programme of India followed by hand on training.



Release of First Guidance Document for Reporting Blood Donor Adverse Reactions



- ❖ National Institute of Biologicals (NIB) celebrated Azadi Ka Amrit Mahotsav: 30 Years of NIB in service to the nation on 30th June, 2022.
- ❖ Dr. Bharti Pravin Pawar, Hon'ble Minister of State, Ministry of Health & Family Welfare, Govt. of India was the chief guest, Shri Rajesh Bhushan, IAS, Secretary, Health & Family Welfare & Prof. Balram Bhargava, Secretary DHR & Director General, ICMR were the guest of honour.
- ❖ On this occasion "Guidance Document for Reporting Blood Donor Adverse Reactions" under National Blood Donor Vigilance Programme (NBDVP) was released by the Hon'ble Minister of State, Ministry of Health & Family Welfare, Government of India.



Meetings organized by NIB

- ❖ A Virtual meeting of experts for Severity Grading Tool (SGT) study under National Blood Donor Vigilance Programme (NBDVP) held on 16th February, 2022 to apprise and deliberate on the trends of analysis.



- ❖ A virtual meeting to discuss draft concept note for inclusion of adverse events related to therapeutic apheresis in Haemovigilance Programme of India (HvPI) held on 25th February, 2022.



- ❖ A Meeting of the Experts held on 24th May, 2022 at National Institute of Biologicals, NOIDA.



New Members Enrolled under Haemovigilance Programme of India (75)

Andhra Pradesh

1. KIMS Hospital Blood Centre, Prakasam Dist.
2. New Life Blood Centre, Visakhapatnam
3. New Life Blood Centre, Vizianagaram
4. New Life Blood Centre, Nellore
5. Konaseema Institute of Medical Sciences & Research Foundation, East Godavari

Assam

1. Blood Centre Nemcare Hospitals Pvt Ltd, Guwahati, Kamrup (M)
2. Down Town Hospital Blood Centre, Guwahati, Kamrup (M)

Bihar

1. Rotary Anup Blood Bank, Patna
2. Blood Centre of M/s Ruban Memorial Hospital, Ratan Stone Clinic (Unit of Ruban Patliputra Hospital Pvt. Ltd.), Patna

Chhattisgarh

1. Raipur Institute of Medical Sciences Blood Bank, Raipur

Gujarat

1. Lions Blood Centre, Ahmedabad
2. Indian Red Cross Society, Ckheda-District, Nadiad
3. Ayush Blood Centre, Vadodara
4. Jeevandeep Blood Center Managed by: The Student Cultural group of Amreli, Rajkot

Haryana

1. M/s Kainos Blood Centre, Rohtak
2. Lions Blood Centre, Sonipat
3. SMS Blood Centre, Hisar
4. M/s Park Hospital (A Unit of Park Medicenters & Institution Pvt. Ltd.), Gurugram
5. Park Healing Touch Hospital Blood Centre, Ambala City
6. Supreme Blood Centre, Faridabad
7. Adesh Medical College & Hospital, Kurukshetra
8. Nidaan Hospital, Sonipat
9. PK Healthcare Pvt Ltd, Sanar International Hospital, Gurgaon
10. SFG Blood Bank, Rohtak

Jammu & Kashmir

1. Bee Enn General Hospital Blood Centre, Jammu

Karnataka

1. Narayana Hrudayalaya Surgical Hospital Private Ltd., Mysore
2. Cytecure Hospitals Pvt. Ltd. Blood Bank, Bengaluru
3. Hemocare Blood Centre, Bangalore
4. K. C. General Hospital, Bengaluru

Kerala

1. Sree Narayana Institute of Medical Sciences, Ernakulam District
2. District Hospital, Mavelikkara, Alappuzha Dist.
3. NS Memorial Institute of Medical Science, Kollam
4. Malabar Institute of Medical Sciences Ltd. Kannur Dist.
5. Magj Hospital, Mookkannoor, Ernakulam Dist.
6. Travancore Medical College Hospital, Kollam Dist.
7. Lisie Hospital, Ernakulam
8. Mar Baselios Medical Mission Hospital Blood Bank, Ernakulam

Meghalaya

1. William Nagar Civil Hospital Blood Centre, East Garo Hills

Maharashtra

1. Apollo Hospital Blood Centre, Navi Mumbai
2. M/s Jupiter Hospital Blood Centre, Thane (W)
3. Sai Healthcare Foundation Charitable Trusts Sanjivani Blood Centre, Ahmednagar
4. Navi Mumbai Blood Centre, Kharghar
5. Ma Saheb Meenatai Thakre Blood Centre, Navi Mumbai Municipal Corporation Blood Centre, Navi Mumbai
6. Seven Hills Healthcare Private Limited Blood Centre, Andheri (E), Mumbai
7. Holy Spirit Hospital Blood Centre, Andheri (E), Mumbai
8. Smt. Kapoorben Vasanti Lathia Blood Centre, Mumbai
9. Rajarshi Shahu Blood Centre, Kolhapur

New Delhi

1. Blood Centre, Maharaja Agrasen Hospital, Dwarka
2. Tarak Hospital Pvt. Ltd. Blood Bank, Dwarka More
3. Kalra Hospital SRCNC Pvt. Ltd., Kirti Nagar
4. Guru Nanak Dev Charitable Blood Centre, Janak Puri

Punjab

1. Blood Center, IVY Hospital, Amritsar
2. Deepak Hospital, Ludhiana

Rajasthan

1. Shriji Blood Bank, Kota
2. Blood Centre Rajkiya Mahila Chikitsalaya, Ajmer
3. Triveni Blood Bank, Ajmer
4. Kshetrapal Multispeciality & Research Centre, Blood Centre, Ajmer

Tamil Nadu

1. Apollo Speciality Hospitals, Trichy
2. Blood Bank, Govt. Dharmapuri Medical College and Hospital, Dharmapuri
3. Sree Balaji Medical College and Hospital, Chennai
4. Government Thiruvannamalai Medical College Hospital, Thiruvannamalai

Telangana

1. Sunshine Blood Centre (A unit of Sarvejana Healthcare Pvt. Ltd.), Secunderabad
2. RVM Institute of Medical Sciences, Siddipet
3. Government Medical College and General Hospital, Suryapet
4. St. Theresa's Hospital Blood Centre, Hyderabad
5. Sunshine Hospitals Blood Centre (A Unit of Raja Lakshmi Healthcare Pvt. Ltd), Ranga Reddy District
6. Life Voluntary Blood Centre (A unit of Life Voluntary Organization), Hyderabad
7. Omni Hospitals Blood Centre, Hyderabad
8. Indian Red Cross Society, Blood Centre, Hanumakonda
9. New Life Blood Centre, Wanaparthy

Uttar Pradesh

1. Awadh Charitable Blood Bank, Lucknow
2. OM Charitable Blood Centre, Gautam Budh Nagar
3. Allahabad Medical Association Blood Bank, Prayagraj

West Bengal

1. Peerless Hospitex Hospital & Research Center Limited, Kolkata
2. Life Care Medical Foundation Blood Centre, Kolkata



National Institute of Biologicals
Ministry of Health & Family Welfare, Govt. of India
NATIONAL BLOOD DONOR VIGILANCE PROGRAMME
(Haemovigilance Programme of India)
Adverse Blood Donor Reaction Reporting Form



Version 2

A) Donor Information	
Donor Id *: _____	Type of Donation* (a) Whole Blood (b) Apheresis _____ (Platelets/Plasma/Plasma + Platelets/RBC/Granulocyte/Peripheral Blood StemCells/ COVID-19 Convalescent Plasma)
Sex * _____ (Male/Female/Other)	
Weight of Donor (kg) * _____	Height of Donor(cm)* _____
	Donor Type* (a) Voluntary (b) Replacement (c) Family Donor (d) Autologous (First Time/Repeat)
Age/ Date of Birth * Yrs: _____ Month: _____ Days: _____ OR _____	Site of Donation* _____ (Blood Centre/Camp)
Pre-Donation Vitals* Pulse: _____ per min	BP (Systolic): _____ mmHg
	BP (Diastolic): _____ mmHg
	Date of Donation * _____
	Time of Donation Hr _____ Min _____
B) Whole blood Details of Blood Collected/Apheresis Details of Blood Collected	
(a) Whole Blood	
Lot No. of Blood Bag* _____	Volume Collected (ml)* _____
Manufacturer of Blood Bag* _____ (Terumo Penpol Limited/Mitra Industries Pvt. Ltd/ HLL Lifecare Ltd/Fresenius Kabi AG/Fenwal Inc/Polymed/Other)	Expiry Date of Blood Bag* _____
(b) Apheresis	
Lot No. Kit* _____	Volume Collected (ml)* _____
	Expiry Date of Kit* _____
C) Adverse Reaction Details	
Date and Time of reaction* _____ Hr _____ Min _____	Type of Reaction* _____ (Localised/Generalized/Both/ Other Reactions)
Vitals at the time of Reaction Pulse: _____ per min	BP (Systolic): _____ mmHg
	BP (Diastolic): _____ mmHg
	Data Captured* _____ (Onsite/Call back by donor/ Call back by Blood Centre)
	Reaction Time* _____ (Pre-Donation/During Donation/After Donation)
Venipuncture Site* _____ (Left/Right/Both)	Injury* _____ (Yes/No)
Venipuncture* _____ (1/2/>2)	Site of Reaction* _____ (At Donation Site/ Outside Donation Site)
	Donation Completed* _____ (Yes/No)
D) Type of Complications:*	
Localised Complications	
<input type="checkbox"/> A1-Complications mainly characterized by the occurrence of blood outside the vessels	
(a) <input type="checkbox"/> Haematoma (bruise)	
(b) <input type="checkbox"/> Arterial puncture	
(c) <input type="checkbox"/> Delayed(bleeding/Re-bleeding) <input type="checkbox"/> (Within 30 minutes of Donation/After 30 minutes of Donation)	
<input type="checkbox"/> A2-Complications mainly characterized by pain	
(a) <input type="checkbox"/> Nerve injury/irritation	
(b) <input type="checkbox"/> Other Painful arm	
<input type="checkbox"/> A3-Localised infection/inflammation along the course of a vein	
(a) <input type="checkbox"/> Thrombophlebitis	
(b) <input type="checkbox"/> Cellulitis	
<input type="checkbox"/> A4- Allergy (local): Itching and redness at the <input type="checkbox"/> (Venipuncture Site/Medical Adhesive Medicated Tape/Skin Disinfection Area)	
<input type="checkbox"/> A5-Other major blood vessel injury -Serious conditions needing specialist medical diagnosis and attention	
(a) <input type="checkbox"/> Deep venous thrombosis (DVT)	
(b) <input type="checkbox"/> Arteriovenous fistula	
(c) <input type="checkbox"/> Compartment syndrome	
(d) <input type="checkbox"/> Brachial artery pseudoaneurysm	



National Institute of Biologicals
Ministry of Health & Family Welfare, Govt. of India
NATIONAL BLOOD DONOR VIGILANCE PROGRAMME
(Haemovigilance Programme of India)
Adverse Blood Donor Reaction Reporting Form
Version 2



Generalized Complications

☐ **B1-Vasovagal reactions**

- | | | | |
|---|--|---|--|
| (a) <input type="checkbox"/> Generalized Weakness | (b) <input type="checkbox"/> Anxiety | (c) <input type="checkbox"/> Dizziness | (d) <input type="checkbox"/> Nausea |
| (e) <input type="checkbox"/> Vomiting | (f) <input type="checkbox"/> Pallor(skin and lips) | (g) <input type="checkbox"/> Rapid Pulse | (h) <input type="checkbox"/> Convulsions |
| (i) <input type="checkbox"/> Cold extremities | (j) <input type="checkbox"/> Hyperventilation | (k) <input type="checkbox"/> Hypotension | (l) <input type="checkbox"/> Low Vol Pulse |
| (m) <input type="checkbox"/> Feeling of warmth | (n) <input type="checkbox"/> Tetany | (o) <input type="checkbox"/> Loss of bowel or bladder control | (p) <input type="checkbox"/> Cyanosis |
| (q) <input type="checkbox"/> Sweating | (r) <input type="checkbox"/> Loss of Consciousness(LOC) _____(<60 Sec/>60 Sec) | | |

☐ **B2-Allergic reactions (Generalized)**

- | | | |
|--|---|---|
| (a) <input type="checkbox"/> Cyanosis | (b) <input type="checkbox"/> Wheezing | (c) <input type="checkbox"/> Flushing,swelling of eyes,lips or tongue |
| (d) <input type="checkbox"/> Chest tightness | (e) <input type="checkbox"/> Cardiac arrest | |

☐ **B3-Other serious complications related to blood donation**

- | | |
|---|--|
| (a) <input type="checkbox"/> Acute cardiac symptoms(other than myocardial infarction or cardiac arrest) | (b) <input type="checkbox"/> Myocardial infarction(MI) |
| (c) <input type="checkbox"/> Cardiac arrest | (d) <input type="checkbox"/> Transient Ischemic attack (TIA) |
| | (e) <input type="checkbox"/> Death |

Apheresis Complication Yes/No

☐ **C-Complications related to apheresis**

- | | | | | |
|--|---|---|---|---|
| (a) <input type="checkbox"/> Citrate reaction | <input type="checkbox"/> tingling/vibrations-lips,fingers | <input type="checkbox"/> light-headedness | <input type="checkbox"/> Metallic taste | <input type="checkbox"/> Muscle twitching |
| | <input type="checkbox"/> Carpopedal spasm | <input type="checkbox"/> Shock | <input type="checkbox"/> Cardiac arrest | <input type="checkbox"/> Tetany |
| | <input type="checkbox"/> Prophylactic Calcium given before reaction <input type="checkbox"/> (Yes/No) | | | |
| (b) <input type="checkbox"/> Haemolysis during procedure | | | | |
| (c) <input type="checkbox"/> Air embolism | | | | |
| (d) <input type="checkbox"/> Unable to return red cell(>200ml) | | | | |

Other Complication

- ☐ D-Other Reactions Please Specify _____

- Outcome***
- | | | |
|--|--|--|
| <input type="checkbox"/> Resolved on donation site | <input type="checkbox"/> Resolved on follow up | <input type="checkbox"/> Recovered with Sequelae |
| <input type="checkbox"/> Permanently disabled | <input type="checkbox"/> Death following the adverse reactions | <input type="checkbox"/> Unknown |

- Imputability***
- | | | |
|--|--|-----------------------------------|
| <input type="checkbox"/> Definite (Certain) | <input type="checkbox"/> Probable (Likely) | <input type="checkbox"/> Possible |
| <input type="checkbox"/> Unlikely (Doubtful) | <input type="checkbox"/> Excluded | |

Any Other Information or Predisposing Factors for Submitted Reactions : _____



Reporter.....

Date of Report.....

Denominator Data about All Donor

Total Donation in the month (of reporting)

- | | | | |
|---|--|------------------------------------|--|
| <input type="checkbox"/> Whole blood | <input type="text"/> | | |
| Volume of donation (Total)* | No. of 350 ml bags | <input type="text"/> | No. of 450 ml bags <input type="text"/> |
| <input type="checkbox"/> Apheresis if apheresis | <input type="text"/> | RBC <input type="text"/> | Platelets <input type="text"/> |
| | Plasma+Platelets | <input type="text"/> | Granulocyte <input type="text"/> |
| | COVID-19 Convalescent Plasma | <input type="text"/> | Peripheral Blood Stem Cells <input type="text"/> |
| Gender of Donor(Total)* | Male <input type="text"/> | Female <input type="text"/> | Other <input type="text"/> |
| Type of Donation(Total)* | Voluntary <input type="text"/> | Replacement <input type="text"/> | Family Donor <input type="text"/> |
| | | | Autologous <input type="text"/> |
| Donor Types(Total)* | First-Time Donors <input type="text"/> | Repeat Donors <input type="text"/> | |
| Site of Donation(Total)* | Blood Centre <input type="text"/> | Camp <input type="text"/> | |

 सत्यमेव जयते	<div>National Institute of Biologicals</div> <div>Ministry of Health & Family Welfare, Govt. of India</div> <div>(National Coordinating Center)</div> <div>HAEMOVIGILANCE PROGRAMME OF INDIA</div>						 राष्ट्रीय जैविक संस्थान NATIONAL INSTITUTE OF BIOLOGICALS									
Transfusion Reaction Reporting Form (TRRF) For Blood & Blood Components & Plasma Products (Version-2)																
* Mandatory Field																
(A) Patient Information																
Hospital Code No.:																
Patient Initials*:			Gender*:			Blood Group*:										
Hospital Admission No.*:				Age/Date of Birth*:		Yrs	Month	Days	Hrs	Mins	
Primary Diagnosis*:																
Medical History:																
(B) Transfusion Reaction Details*																
Was the patient under anaesthesia during transfusion: Yes/No if Yes type : GA/Spinal/LA																
Pre-transfusion Vitals:						Temp:		Pulse:		BP:		RR:		SPO2:		
Vitals at the time of reaction:						Temp:		Pulse:		BP:		RR:		SPO2:		
Please tick mark the relevant signs and symptoms listed below																
Generalised			Pain		Respiratory		Renal		Circulatory							
<input type="checkbox"/>	Fever		<input type="checkbox"/>	Anxiety	<input type="checkbox"/>	Chest Pain		<input type="checkbox"/>	Dyspnoea		<input type="checkbox"/>	Haematuria		<input type="checkbox"/>	Tachycardia	
<input type="checkbox"/>	Chills		<input type="checkbox"/>	Itching (Pruritus)	<input type="checkbox"/>	Abdominal		<input type="checkbox"/>	Wheeze		<input type="checkbox"/>	Haemoglobinuria		<input type="checkbox"/>	Hypertension	
<input type="checkbox"/>	Rigors		<input type="checkbox"/>	Edema (Site)_____	<input type="checkbox"/>	Back/Flank Pain		<input type="checkbox"/>	Cough		<input type="checkbox"/>	Oliguria		<input type="checkbox"/>	Hypotension	
<input type="checkbox"/>	Nausea		<input type="checkbox"/>	Juandice	<input type="checkbox"/>	Infusion Site Pain		<input type="checkbox"/>	Hypoxemia		<input type="checkbox"/>	Other _____		<input type="checkbox"/>	Raised JVP	
<input type="checkbox"/>	Urticaria		<input type="checkbox"/>	Other _____	<input type="checkbox"/>	Other _____		<input type="checkbox"/>						<input type="checkbox"/>	Arrhythmias	
<input type="checkbox"/>	Flushing								Bilateral Infiltrates on					<input type="checkbox"/>	Other _____	
<input type="checkbox"/>	Restlessness								Chest X-ray							
<input type="checkbox"/>	Vomiting							<input type="checkbox"/>	Other							
Any Other(Specify) : _____																
(C) Transfusion Product(s) Details*																
Select*	Select Component	Select Indication	Date & Time of Issue of Blood Component	Date & Time of onset Transfusion	Unit Id (Transfused)	Blood Group	Volume Transfused (ml)	Expiry date of Blood Component	Manufact urer of Blood Bag	Batch / Lot No. of the Blood Bag	1st time/ repeat Transfusion					
<input type="checkbox"/>	Saline Washed Red Cells										<div><input type="checkbox"/> 1st Time</div> <div><input type="checkbox"/> Repeat 1 to 10</div> <div><input type="checkbox"/> Repeat > 10</div>					
<input type="checkbox"/>	COVID-19 Convalescent Plasma															
<input type="checkbox"/>	Whole blood															
<input type="checkbox"/>	Packed Red blood cells (PRBC)															
<input type="checkbox"/>	Buffy coat depleted PRBC															
<input type="checkbox"/>	Leucofiltered PRBC															
<input type="checkbox"/>	Random Donor platelets/ pooled															
<input type="checkbox"/>	Apheresis Platelets															
<input type="checkbox"/>	Fresh Frozen Plasma															
<input type="checkbox"/>	Cryoprecipitate															
<input type="checkbox"/>	Any Other															
Add New Plasma Product																
Select	Plasma Product	Indication	Date of Administration	Manufacturer	Expiry Date of the Plasma Product	Batch No. / Lot No.	1st Time / Repeat									
							<div><input type="checkbox"/> 1st Time</div> <div><input type="checkbox"/> Repeat 1 to 10</div> <div><input type="checkbox"/> Repeat > 10</div>									

TRANSFUSION REACTION REPORTING FORM (TRRF VERSION-2)

(D) Investigations									
<input type="checkbox"/> Clerical Checks		Specify Error Found if any: _____							
Investigation		Pre-transfusion sample				Post-transfusion sample			
<input type="checkbox"/>	Visual Check								
*	<input type="checkbox"/> Repeat Blood Grouping	O+ /A+ /B+ /AB+ /O- /A- /B- /AB-				O+ /A+ /B+ /AB+ /O- /A- /B- /AB-			
*	<input type="checkbox"/> Repeat Crossmatch	<input type="checkbox"/> Compatible <input type="checkbox"/> InCompatible <input type="checkbox"/> Not Done				<input type="checkbox"/> Compatible <input type="checkbox"/> InCompatible <input type="checkbox"/> Not Done			
*	<input type="checkbox"/> Repeat Antibody screen	<input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Not Done				<input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Not Done			
	<input type="checkbox"/> Antibody Identification								
*	<input type="checkbox"/> Direct antiglobulin test	<input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Not Done				<input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Not Done			
	<input type="checkbox"/> Hemoglobin								
	<input type="checkbox"/> Plasma Hemoglobin								
	<input type="checkbox"/> Urine hemoglobin								
	<input type="checkbox"/> Bilirubin (Total/conjugated)								
	<input type="checkbox"/> Platelet count								
	<input type="checkbox"/> PT/INR								
*	<input type="checkbox"/> Blood culture of Blood Bag	<input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Not Done				Specify Organism if positive _____			
*	<input type="checkbox"/> Blood culture of Patient	<input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Not Done				<input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Not Done Specify Organism if positive _____			
	<input type="checkbox"/> Chest X-ray of the patient in case of suspected TRALI								
In case of Non-immune hemolysis (which of the following was the case?)									
<input type="checkbox"/> Hemolysis due to freezing of PRBC Units									
<input type="checkbox"/> Hemolysis due to inappropriate warming of PRBC Units									
<input type="checkbox"/> Hemolysis due to infusion of any other fluid through same BT set. Specify Fluid: _____									
<input type="checkbox"/> Mechanical damage									
In Case of ABO Mismatch (which of the following was the case?)									
<input type="checkbox"/> Wrong Blood in tube									
<input type="checkbox"/> Grouping error									
<input type="checkbox"/> Labelling error									
<input type="checkbox"/> Wrong unit transfused									
(E) Nature of Adverse Reaction(s)*									
Select	Reaction				Date & Time of Onset of Reaction	Date & Time of Recovery	Outcome		
<input type="checkbox"/>	Febrile Non Haemolytic Reactions (FNHTR) 1° C rise in temperature <input type="checkbox"/> 2° C rise in temperature <input type="checkbox"/> Only Chills & Rigors <input type="checkbox"/>						<input type="checkbox"/> 1. Death following the Adverse Reaction(s)		
<input type="checkbox"/>	Allergic reaction						<input type="checkbox"/> 2. Recovered		
<input type="checkbox"/>	Anaphylaxis								
<input type="checkbox"/>	Immunological Haemolysis due to ABO Incompatibility								
<input type="checkbox"/>	Immunological Haemolysis due to other Allo-Antibodies								
<input type="checkbox"/>	Non Immunological Haemolysis						<input type="checkbox"/> 3. Recovered with Sequelae		
<input type="checkbox"/>	Hypotensive Transfusion Reaction						<input type="checkbox"/> 4. Unknown		
<input type="checkbox"/>	Transfusion Related Acute Lung Injury (TRALI) Definite <input type="checkbox"/> Possible <input type="checkbox"/>								
<input type="checkbox"/>	Transfusion Associated Dyspnoea (TAD)								
<input type="checkbox"/>	Transfusion Associated Circulatory Overload (TACO)								
<input type="checkbox"/>	Transfusion Transmitted Bacterial Infection								
<input type="checkbox"/>	Transfusion Transmitted Parasitic Infection (Malaria)								
<input type="checkbox"/>	Post Transfusion Purpura								
<input type="checkbox"/>	Transfusion Associated Graft versus Host Disease (TAGvHD)								
<input type="checkbox"/>	Other Reaction (s) _____ <input type="button" value="Add New"/>								
IMPUTABILITY ASSESSMENT									
(F) Imputability Assessment*									
S. No.	Reaction Term	Transfusion Product/ Component	*Imputability Assessment (Please mention from the below list)						
*Imputability: 1. Definite (Certain), 2. Probable (Likely), 3. Possible, 4. Unlikely (Doubtful), 5. Excluded, 6. Not Assessed									
Monthly Denominator Reporting Form *									
Hospital Code :					Month/Year:				
Blood Component					No. of Units Issued				
1) Saline Washed Red Cells									
2) COVID-19 Convalescent Plasma									
3) Fresh Frozen Plasma									
4) Whole Blood									
5) Packed Red Blood Cells (PRBC)									
6) Buffy Coat Depleted PRBC									
7) Leucofiltered PRBC									
8) Random Donor Platelets/ Pooled									
9) Apheresis Platelets									
10) Cryoprecipitate									
11) Any Other _____									

Who can enrol?


How to enrol?

- 1) Head / Incharge of Transfusion Medicine Department / Blood Centre provides the necessary details to the National Coordinating Centre (NCC) - Haemovigilance Programme of India (HvPI) by sending the duly filled **Enrolment Form** either to NCC at National Institute of Biologicals, Ministry of Health & Family Welfare, Plot No. A-32, Sector-62, Institutional Area, NOIDA - 201 309 (U.P.) or via E-mail to NCC at **haemovigilance@nib.gov.in**
- 2) NCC verifies the details provided by the centre.
- 3) After verification, NCC issues the User Id and Password to the Head / Incharge of Transfusion Medicine Department / Blood Centre to access the (a) Haemo - Vigil Software (b) Donor-Vigil Software for onward Submission of Transfusion Reactions Reports and Adverse Blood Donor Reaction Reports to NCC.

Download Enrolment Form from the website:- <http://nib.gov.in/media/Annexure7.pdf>

Reporting of Adverse Transfusion Reactions via Haemo-Vigil Software & Adverse Blood Donor Reactions in donation via Donor-Vigil Software.

- Centres enrolled under HvPI receives unique User Id & Password from NCC-HvPI, NIB.
- User Id & Password is same for both the Softwares i.e. Haemo-Vigil (to report adverse transfusion reactions) & Donor-Vigil (to report adverse donor reactions).
- Software(s) link is available at NIB website i.e. **www.nib.gov.in** under the tab of Haemovigilance Programme of India.
- The adverse reaction reports can be uplinked and submitted online via the above mentioned software(s) to NCC-HvPI, NIB.



भारत सरकार | Government of India


(राष्ट्रीय जैविक संस्थान)
National Institute of Biologicals
 स्वास्थ्य एवं परिवार कल्याण विभाग, भारत सरकार
 Ministry of Health & Family Welfare, Government of India

www.nib.gov.in

[Click here for Old NIB Website](#)

[Home](#)
[About Us](#)
[SRRD Unit](#)
[Laboratories](#)
[Biological Standards](#)
[Procurement](#)
[Careers](#)
[Directory](#)
[Employee Corner](#)
[Contact Us](#)
[Help](#)

[**Mandatory documents for COVID-19 kits / VTM submission**](#)
[** Sample Submission Guidelines**](#)
[** KIND AT LEAST](#)



Welcome to NIB

The National Institute of Biologicals (NIB) had been set up in 1992. NIB is an apex autonomous institute under the administrative control of Ministry of Health & Family Welfare (MoHFW), Government of India. The Institute is located at A-32, Sector-62, NOIDA, Uttar Pradesh in an area of 74,000 Sq. M.

The Institute is performing primary statutory function of Quality Control of Biologicals e.g. Insulin, erythropoietin, blood products, diagnostic kits e.g. HIV, HBV, HCV, therapeutic monoclonal antibodies like Trastuzumab and Rituximab used in cancer treatment etc. in accordance with provisions of Drugs & Cosmetics Act 1940 and Rule 1945 amended from time to time. The Immunodiagnostic kit Laboratory of the Institute is a WHO Collaborating Centre for Quality Control of HIV, HCV, HBsAg and Syphilis In-Vitro Diagnostic Assays and Support Cell for WHO Pre-Qualification Programme for In-Vitro Diagnostics.

Institute is NABL accredited for ISO/IEC 17025:2017 as per the scope defined for discipline of Biological testing and Chemical testing in Biological products.

The Institute is notified Central Drugs Laboratory and Central Medical Device Testing Laboratory under these statutory provisions. The biological products are tested as per statutory standards laid down in Indian Pharmacopoeia or relevant pharmacopoeia or International norms, in the NIB Laboratories. The laboratories are also accredited by NABL as per the scope defined. Some of the NIB scientists have also been notified as Government Analysts and Medical Device Testing Officers for biological products as per Statutory Norms.

The scientists of the institute are committed towards their duty and follow the mandates and functions meticulously. Some of them are as hereunder:

[Click here](#)
[Haemovigilance Programme of India](#)

[Click here](#)
[Upcoming Trainings at NIB](#)

[What's New](#)

PM to 06:00 PM through online mode).
 For more information kindly visit website
<http://ivpi.azurewebsites.net> For any
 query related to conference kindly call at
 Toll Free number i.e:- 1800-150-2588 or
 mail us at contactivpi@gmail.com

CDL Notification for Covid 19 Vaccine



National Institute of Biologicals- National Coordinating Centre-HvPI

ACKNOWLEDGEMENT

NCC-HvPI acknowledges the contribution by Ms. Ruchi Rao (Technical Consultant), Mr. Akash Chaudhary (Bench Biologist), Ms. Sangeeta Yadav & Mr. Sushant Panchal (Data Entry Operators) of Haemovigilance Division, NIB for their contribution in bringing out this issue of HvPI Newsletter.

National Institute of Biologicals

Ministry of Health and Family Welfare, Government of India
A-32, Sector-62, Near NH-24, Noida - 201309, Uttar Pradesh

NIB website: <http://nib.gov.in/>

Email: haemovigilance@nib.gov.in

Tel: 0120-2400072, 0120-2593612 Fax: 0120-2403014

**Toll free No. 1800-180-2588 [Mon to Fri (9:00 a.m. to 5:30 p.m.)]
query related to Haemovigilance Programme of India.**

For any other Information/ Suggestions/ Query related to Haemovigilance Programme of India kindly contact: Dr. Akanksha Bisht, Scientist Grade-II & Head-Haemovigilance Programme of India, NIB, NOIDA at: haemovigilance@nib.gov.in